Skip to main content
Lotus Endometriosis Institute solid color logo
A beautiful landscape of lotus flowers

Relugolix for Endometriosis Pain: What a 2025 Meta-Analysis Says About Relief, Quality of Life, and Side Effects

What the latest evidence says about pain relief, quality of life (EHP-30), side effects, add-back therapy, and how relugolix compares to leuprorelin.

By Dr Steven Vasilev
A Black woman in a modern home office reviews a laptop showing a clean forest plot comparing relugolix and leuprorelin with an EHP-30 chart, a note about add-back therapy, and a pill organizer on the desk.

Living with endometriosis can mean dealing with persistent pelvic pain, painful periods, and the emotional toll of symptoms that affect work, relationships, and daily routines. Newer oral medications—like relugolix—are being studied and used to help reduce endometriosis-associated pain and improve quality of life.


This post summarizes patient-relevant findings from a 2025 systematic review and meta-analysis of randomized controlled trials (RCTs)published in Frontiers in Endocrinology that evaluated relugolix using the Endometriosis Health Profile-30 (EHP-30), a common endometriosis quality-of-life questionnaire.


What is endometriosis—and why can it hurt so much?


Endometriosis is often described as a chronic condition where tissue similar to the lining of the uterus is found outside the uterus. Many people experience pain that can be intense and life-disrupting. This meta-analysis focused on endometriosis-associated pain and how treatment affected pain and quality of life as captured by EHP-30 scores.


How does relugolix work?


Relugolix is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist. In plain language: it works by reducing hormonal signals that contribute to endometriosis-related pain.


The review also discusses a key practical difference from some older GnRH-based treatments (like GnRH agonists such as leuprorelin): relugolix may provide comparable benefit without an initial “flare-up” of symptoms that can happen when starting a GnRH agonist. (The paper emphasizes non-inferiority vs leuprorelin and notes the lack of a flare-up as a potential advantage.)


Does relugolix reduce endometriosis pain? What the evidence shows


Across the included RCTs, relugolix was associated with meaningful improvements in EHP-30 pain-related outcomes—especially compared with placebo (no active treatment).


Key findings (vs placebo):

  • Improved EHP-30 Pain domain scores: mean difference (MD) 6.77(95% CI 3.15 to 10.39, p=0.0002)
  • Higher likelihood of being a “responder” on the EHP-30 Pain domain: odds ratio (OR) 3.245(95% CI 2.496 to 4.219, p < 0.0001)


What this means for patients: in these studies, people taking relugolix were more likely to report meaningful pain improvement than those taking placebo.


Beyond pain: quality-of-life improvements (EHP-30 domains)


Endometriosis isn’t only about pain levels—it can affect mood, relationships, and self-confidence. In this meta-analysis, relugolix also improved several quality-of-life areas compared with placebo:

  • Emotional well-being: MD 5.71(95% CI 1.87 to 9.55, p=0.0036)
  • Social support: MD 6.40(95% CI 0.88 to 11.93, p=0.0231)
  • Self-image: MD 6.00(95% CI 1.03 to 10.96, p=0.0179)


If you’ve felt that endometriosis affects your mental health or sense of self, these findings are important: the research suggests relugolix may help improve how you feel and function, not just pain scores.


How does relugolix compare with leuprorelin (an older GnRH treatment)?


Some trials compared relugolix with leuprorelin (a GnRH agonist). The review concludes that:

  • Relugolix is generally non-inferior (meaning “not worse”) compared with leuprorelin.
  • It was not statistically superior (not clearly better) for overall efficacy or quality-of-life impact.
  • In results summarized by the authors, relugolix showed a numerically smaller improvement than leuprorelin in at least one analysis (reported as MD -3.79, 95% CI -6.27 to -1.31), and the discussion notes the confidence intervals did not show clear superiority.


Patient takeaway: Relugolix may be an alternative option with similar overall benefit, and it may avoid the initial symptom flare associated with starting a GnRH agonist—an issue some patients find difficult.


Ready to Tackle Endometriosis Pain?

Our specialists are here to help you understand your condition and explore your treatment options.

Schedule Your Consult

Side effects and “add-back” therapy: what to know


Like many treatments that reduce estrogen activity, relugolix can cause hypoestrogenic side effects (symptoms related to lower estrogen).


The meta-analysis reports common adverse events such as:

  • Hot flushes(noted as frequent and dose-dependent)
  • Headache
  • Fatigue
  • Musculoskeletal pain
  • Nasopharyngitis


The paper also highlights the role of combination (“add-back”) therapy—relugolix used with estradiol and norethisterone acetate—which is designed to help mitigate hypoestrogenic side effects while maintaining benefit.


Important note: The article indicates that add-back therapy helps with tolerability and management of hypoestrogenic effects, but the blog data provided here does not include specific numerical results for every side-effect rate or discontinuation rate by regimen—so we can’t quantify exactly how much add-back reduces each side effect from this summary alone.


Relugolix combination therapy vs relugolix alone: is one better?


In subgroup analyses:

  • Combination therapy showed a numerically larger improvement (MD 8.86) than
  • Monotherapy (MD 4.99)

However, the authors report the difference between subgroups was not statistically significant. In other words, combination therapy may look better in numbers, but this meta-analysis could not confirm it is definitively better for pain outcomes based on the available trial data.


Is relugolix effective long term?


This is one of the biggest unanswered questions. The review notes that:

  • Benefits were most clearly demonstrated around 24 weeks
  • For longer follow-up periods (including 52 and 104 weeks), the confidence intervals crossed zero, meaning the meta-analysis could not conclusively demonstrate continued significant benefit at those extended durations


What this means for you: If you and your clinician are considering relugolix beyond 6 months, it’s reasonable to ask about:

  • symptom monitoring plans,
  • side effect management (including add-back therapy),
  • and what is known (and not known) about longer-term outcomes.


Actionable takeaways: questions to bring to your next appointment


If you’re considering relugolix for endometriosis-associated pain, these discussion points can help:


1. Am I a good candidate for an oral GnRH antagonist?

Ask how relugolix fits with your symptoms, prior treatments, and preferences.


2. Should I use relugolix alone or relugolix combination (add-back) therapy?

This review suggests add-back is important for managing hypoestrogenic effects; the pain benefit difference vs monotherapy wasn’t statistically definitive.


3. What side effects should I watch for, and how will we manage them?

Hot flushes, headache, fatigue, and muscle aches were commonly reported; hot flushes were dose-dependent.


4. What’s the plan for follow-up at 24 weeks—and beyond?

Long-term benefit past 24 weeks was not clearly established in this meta-analysis, so having a reassessment timeline matters.


Cautions and gaps: avoiding common misunderstandings


Based on the authors’ discussion, it’s worth keeping these points in mind:

  • Don’t assume long-term benefit is guaranteed. Evidence beyond ~24 weeks is limited/inconclusive in this analysis.
  • Don’t assume relugolix is “better than” leuprorelin. It appears comparable overall (non-inferior), but not clearly superior.
  • Don’t minimize side effects. Many are tied to lower estrogen, and the paper highlights the importance of add-back therapy for tolerability.
  • Results can vary between people and studies. The meta-analysis reported substantial heterogeneity (I² reported as 90.7%), suggesting responses may differ depending on regimen, comparator, and other study factors.

References

  1. Xie J, Ni X, Huang Q, Guo Y. Relugolix’s impact on endometriosis-associated pain and quality of life: a meta-analysis of EHP-30 outcomes. Frontiers in Endocrinology. 2025. (Systematic review and meta-analysis of RCTs; PRISMA-guided.) DOI: 10.3389/fendo.2025.1650579

Quick Answers

How rare is endosalpingiosis?

Endosalpingiosis is generally considered uncommon, but “how rare” it is depends heavily on who’s being studied and how it’s found. Many cases are discovered incidentally on pathology—meaning tissue is identified under the microscope after surgery done for other reasons—so it’s likely underrecognized in the general population. In other settings (like surgical cohorts), it may appear more often simply because more tissue is being sampled and examined carefully.


What matters most for patients is that endosalpingiosis can be confused with endometriosis on imaging or even at surgery, yet it doesn’t always behave the same way clinically. If you’ve been told you have endosalpingiosis and you also have pelvic pain, bowel/bladder symptoms, or fertility concerns, our team can help interpret what that finding means in the context of your symptoms and operative/pathology reports. You’re welcome to explore our educational content on related endometriosis and uterine conditions, and reach out to schedule a consultation if you want a personalized plan.

Read full answer

How does estrogen affect the endometrium?

Estrogen is one of the main hormones that drives endometrial growth. In the first half of the menstrual cycle, rising estrogen signals the endometrium to thicken and rebuild after a period, preparing the uterus for a possible pregnancy. It also influences the local immune and inflammatory environment in the uterus, which is part of why hormonal shifts can change bleeding patterns and pain.


When estrogen’s growth signals are strong—and progesterone’s “calming” effect is weaker than expected (often described as progesterone resistance)—the endometrium can behave in a more persistently inflamed, reactive way. This hormone–inflammation pattern is especially relevant in estrogen-dependent conditions like adenomyosis and endometriosis, where tissue similar to the endometrium can contribute to ongoing symptoms. If you’re trying to make sense of heavy bleeding, severe cramping, or cycle-linked pelvic pain, our team can help you connect the hormonal biology to what you’re feeling and review next steps for diagnosis and treatment.

Read full answer

What does a frozen uterus mean with endometriosis?

A “frozen uterus” isn’t a separate diagnosis—it’s a descriptive term surgeons use when the uterus is essentially stuck in place because endometriosis-related inflammation has caused dense scarring (adhesions). Instead of the uterus moving freely, it may be tethered to nearby structures like the bowel, bladder, ovaries, or pelvic sidewall, sometimes pulling the uterus into an abnormal position and making pelvic anatomy hard to distinguish.


This finding often suggests more advanced disease, such as deep infiltrating endometriosis and/or significant adhesions from prior inflammation or surgery, and it can help explain symptoms like deep pelvic pain, painful sex, bowel or bladder symptoms, or pain that doesn’t match what a routine exam shows. In these cases, surgery is less about “burning spots” and more about carefully restoring normal anatomy—freeing organs, protecting ureters and bowel, and removing endometriosis at its roots. If you’ve been told your uterus is “frozen,” our team can help you understand what that implies for imaging, surgical planning, and which adjacent organs may need to be evaluated as part of a complete excision strategy.

Read full answer

What are peritoneal pockets in endometriosis?

Peritoneal pockets are small “indentations” or fold-like defects in the peritoneum—the thin lining that covers the pelvic organs and inner abdominal wall. In endometriosis surgery, we may see these pockets as tucked-in areas or little pits in the peritoneal surface, and they can be associated with superficial peritoneal endometriosis or early/developing disease patterns.


These pockets matter because endometriosis doesn’t always look like obvious black or red implants; it can hide within subtle anatomic changes, scarring, or altered peritoneal contours. In the operating room, careful inspection and technique are important so that disease within or around a peritoneal pocket isn’t missed or only treated on the surface. If you’ve been told you have “peritoneal pockets,” our team can help you understand what that finding may mean in your case—based on your symptoms, imaging, and whether deeper structures (like bowel, bladder, or ureters) could also be involved.

Read full answer

How long do endometriosis flare-ups last?

Endometriosis flare-ups don’t have one “usual” length—some people feel a spike in symptoms for a few hours to a couple of days, while others have flares that stretch across an entire cycle window or blend into more constant pain. Many flares track with hormonal shifts (often before and during a period), but bowel, bladder, pelvic floor, or nerve-related pain can flare at different times and may not follow a neat calendar pattern.


When flares start lasting longer or happening more often, it can be a sign that multiple pain drivers are stacking—ongoing inflammation from lesions, adhesions/fibrosis that can “tether” organs, and sometimes central sensitization, where the nervous system becomes more reactive over time. That’s why symptom management alone can feel like a band-aid if active disease is still present. If you’re noticing prolonged, unpredictable, or escalating flares, our team can help you map your pattern, identify what’s likely driving it, and discuss a plan that addresses both symptom control and the underlying endometriosis.

Read full answer

Reach Out

Have a question?

Dr. Steven Vasilev delivers best-in-class endometriosis guidance and a personalized treatment plan—built on evidence and your unique biology.


Led by Steven Vasilev, MD—an internationally recognized endometriosis specialist & MIGS surgeon—Lotus Endometriosis Institute is virtual-forward, with many patients traveling nationally for care. Clinical evaluation and surgical treatment are provided in California.

Santa Monica, CA

2121 Santa Monica Blvd, Santa Monica, CA 90404

Operating Hours

8:00 am - 5:00 pm
Monday - Friday

Arroyo Grande, CA

154 Traffic Way, Arroyo Grande, CA 93420